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Bone resorption and mRNA expression of IL-6 and IL-6 receptor in
patients with renal osteodystrophy. The cytokine interleukin-6 (IL-6) is a
major cell regulatory factor that may play an important role in the bone
remodeling of patients with renal failure. IL-6 exerts its action by binding
to its receptor (IL-6R), which leads to transduction of a second messenger
cascade within cells. In vitro as well as in viva data point to IL-6 as an
autocrine/paracrine factor in bone osteoclasts. Recently, bone cells from
patients with Paget's disease were found to express IL-6 and IL-6R mRNA
transcripts. However, in patients with renal bone disease, there is currently
no in viva evidence that osteoclasts have the capability to express mRNA
for IL-6 and IL-6R. To investigate the potential expression of IL-6 and
IL-6R in bone and its relationship to bone cell activity, iliac crest bone
biopsies were performed in patients on chronic maintenance dialysis.
Messenger RNA expression of IL-6 and IL-6R was studied using in situ
hybridization histochemistry, and parameters of bone turnover were
determined by bone histomorphometry. In the samples studied, mRNA
expression of IL-6 and IL-6R was found in osteoclasts and bone marrow
cells. Furthermore, we report the novel finding of increased IL-6R mRNA
expression in osteoclasts engaged in increased bone resorption. The
results of the present study suggest that the cytokine IL-6 is intricately
involved in osteoclastic bone resorption and that expression of its recep-
tor, IL-6R, in osteoclasts may parallel osteoclastic bone resorbing activity.
Although the functional role of IL-6 clearly points to its
importance in bone remodeling, very little is known of the cellular
localization in bone cells for IL-6 and IL-6R mRNAs in vivo. The
only in vivo evidence of IL-6 and IL-6R expression, particularly in
osteoclasts, is documented in patients with Paget's bone disease
[11] suggesting that IL-6 may be an autoregulatory factor in these
cells. There is currently no other molecular histologic evidence
that this cytokine and/or its receptor are expressed in other
metabolic bone diseases such as renal bone disease.
Renal osteodystrophy is a good model for the study of the
relationship between IL-6, its receptor, IL-6R, and bone resorp-
tion. It is a disease that presents a wide range of bone remodeling
abnormalities [2, 12]. Therefore, the present study was carried out
to investigate the interaction between IL-6 and IL-6R mRNA
expressions and bone resorption in iliac crest biopsies of patients
with chronic renal failure.
Methods
Tissue sources and preparation
The cytokine interleukin-6 (IL-6) is postulated to play a signif-
icant role in bone remodeling by its ubiquitous presence in the
bone microenvironment [1—4]. This cytokine exerts its cellular
actions through its receptor (IL-6R), an 80 kDa ligand-binding
protein, and a homodimer signal transducing glycoprotein 130 [5],
triggering a second messenger cascade [6]. Osteoclast-progenitor
cells as well as osteoblast-like cells in vitro can produce IL-6 [3, 7].
IL-6 can stimulate differentiation and proliferation of osteoclast
precursor cells [3, 7, 8] and in vivo reports suggest that IL-6 may
induce hypercalcemia, osteoclast formation, and subsequently,
increased bone resorption [9]. Recent data demonstrated a direct
stimulatory effect of IL-6 in osteoclasts' ability to produce cathep-
sin L, a cysteine proteinase indicative of the osteoclastic bone
resorption process [10]. IL-6 induced dose-dependent increases of
cathepsin L activity without affecting the overall number of
osteoclasts.
Bone samples were taken from seven patients that were on
chronic maintenance dialysis using an electric drill (Straumann
AG, Waldenburg, Switzerland). The patients were under local
anesthesia during the procedure [13]. Biopsies from the anterior
iliac crest were immediately fixed in fresh 4% paraformaldehyde
at 4°C for 24 hours. Acetone dehydration, cold polymerization in
methyl methacrylate (MMA), and plastic-embedding in MMA
followed [14]. Serial sections 5 jim thick were cut with a Microm,
model HM360 microtome (C. Zeiss, Thornwood, NY, USA).
For mineralized bone histology, sections were stained with the
modified Masson-Goldner trichrome stain [15]. In addition, sec-
tions were stained with aurin tricarboxylic acid stain [16] and
solochrome azurine [171 for detection of aluminum. Unstained
serial sections were also prepared for phase contrast and fluores-
cent light microscopy.
In situ hybridization
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Following plastic removal using 2-methoxyethyl acetate, tissue
sections were deproteinated with proteinase K (0.1 jig/ml) for 15
minutes at 37°C to allow probe penetration, subsequently rinsed
in 0.2% buffered glycine, washed in 0.1 M triethanolamine for five
minutes, and acetylated for 15 minutes with the addition of 0.25%
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acetic anhydride. The slides were then rinsed in 2X SSC and
dehydrated through graded alcohols.
Hybridization riboprobe protocol. Riboprobes for human IL-6
and IL-6R mRNAs were obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA). The IL-6 probe (ca 1.0
kb) was subcloned into the EcoRI site of pGEM7Zf and the T7
and SP6 RNA polymerases were utilized to generate the sense
and anti-sense RNAs, respectively. The IL-6R probe (ca 1.2 kb)
was subcloned into pBluescript KS. Sense and anti-sense RNAs
were made by linearization with either EcoRI or Barn HI and using
T7 or T3 RNA polymerases. The probes were generated in
accordance with standard transcription protocols using MAXI-
script in vitro transcription kit (Ambion Inc., Austin, TX, USA).
Briefly, RNAse-free water, lOx transcription buffer, 200 mM
DII, 10 mM aliquots of ATP, CTP and GTP, and 12.5 U of
RNAse inhibitor were combined with I xg of linearized DNA
template, 10 U of appropriate polymerase and 40 jxCi 35S-UTP to
a 20 tl volume. Transcription reaction occurred at 37°C for one
hour followed by digestion of template with 2 U of DNAseI and
ethanol precipitation with 5 M NH4OAc, 100 mivi EDTA, 100%
EtOH, and 6 jxg yeast tRNA at —70°C for one hour. Pellets were
resuspended in sterile RNAse-free water. Specific activities of
synthesized probes were determined to be 1.4 x IO cpm/xg for
IL-6 and 7.4 x 108 cpm/tg for IL-6R antisense riboprobes.
Fidelity of the probes was verified by 4% polyacrylamide gel
electrophoresis of aliquots of respective probes. Controls for the
experimental protocol included (1) tissue sections pretreated with
RNAse A prior to proteinase K treatment and hybridization with
antisense probes and (2) hybridization with sense-strand probes.
In situ hybridization histochemistty protocol. One million cpm of
synthesized probe in 50 pA of hybridization buffer (Amresco,
Solon, OH, USA), containing 50% formamide was applied to
each slide. The diluted probe was placed on appropriately sized
coverslips, which were subsequently applied to tissue sections.
The slides were then placed in a chamber humidified with 50%
formamide and incubated overnight at 50°C. The following day,
coverslips were taken off in 2x SSC and unbound probe was
digested in 100 xg/ml RNAse A. The slides were washed twice in
0.2x SSC (10 mm/wash), incubated in 0.2X SSC at 65°C for one
hour, then transferred into fresh 0.2x SSC. Dehydration through
graded ethanols and air diying followed. The slides were subse-
quently prepared for X-ray and/or emulsion autoradiography with
BioMax MR film or NTB2 emulsion (Kodak, Rochester, NY,
USA).
Data analysis. The emulsion-dipped images were analyzed using
a Zeiss Universal microscope (C. Zeiss, Thornwood, NY, USA)
mounted with a Motion Analysis video camera, a Power Macin-
tosh 8500 AV computer, and the NIH image software program.
Histologic optical fields at 125 x magnification were examined.
The minimum number of osteoclasts assessed was determined by
evaluating an increasing number of osteoclasts ranging from 20 to
100 cells. It was found that more than 50 osteoclasts did not
change the mean and SD of the labeling intensity. Therefore, a
minimum of 50 osteoclasts were analyzed in each sample. To
qualitatively analyze the hybridization labeling density of the
respective mRNAs, discrete cell bodies were scored on a graded
scale. The grading criteria were: + for < 10 grains/cell; + + for
10 to 50 grains/cell; + -4- + for 50 to 80 grains/cell; + + + + for
grains confluent.
Bone histomorphomety
Static and dynamic parameters of bone structure, formation,
and resorption were measured with the Osteoplan System II
(Kontron, Munich, Germany) [18]. A minimum of 50 optical fields
was evaluated at a magnification of 200 X through the use of an
objective with a numerical aperture of 0.4 using a Universal
microscope (C. Zeiss, Thornwood, NY, USA). Erosion depth,
which reflects osteoclast activity was calculated using the rectan-
gular model from the area and length of the erosion cavity
obtained by reconstruction [19-21]. All parameters comply with
the nomenclature published by the histomorphometry nomencla-
ture committee of the American Society of Bone and Mineral
Research [22].
Measurement of serum parathyroid hormone (PTH) levels
Concentrations of serum PTH were determined in duplicate by
the two-site immunoradiometric assay (IRMA) for intact PTH
[23] using the AllegroTM Intact PTH assay kit (Nichols Institute,
San Juan Capistrano, CA, USA). The interassay variation was 4%.
Statistical analysis
Results are expressed as mean SEM. Bivariate correlations
were carried out using the Spearman rank test.
Results
Among the seven patients studied, there were four men and
three women with a mean age of 48.8 7.2 years (range 23 to 72
years) on chronic maintenance dialysis for a duration of 2.5 0.6
years (range 10 months to 5 years). All patients had serum PTH
levels above the normal range of 65 pg/mi (Table 1). Mineralized
bone histology showed predominant hyperparathyroidism in three
patients and mixed uremic osteodystrophy (such as association of
secondary hyperparathyroidism with various degrees of a miner-
alization defect) in four patients (Table 1). None of the patients
exhibited stainable aluminum at the bone-osteoid interface. The
parameters of bone erosion are shown in Table 1. Serum PTH
levels correlated with parameters of bone resorption (r =0.84—
0.94, P < 0.02).
IL-6 and IL-6R mRNA expression
All osteoclasts in bone tissue sections contained positive hy-
bridization signals for IL-6 and IL-6R mRNAs (Fig. 1). The
positive signal for IL-6 mRNA was easily observed, and oste-
ociasts contained 20 to 50 grains per cell (Fig. iF). However, no
marked difference was observed in the labeling intensity for IL-6
mRNA (Table 1).
In contrast to IL-6 mRNA labeling intensity, the hybridization
signals for IL-6R mRNA in osteoclasts differed markedly from
patient to patient (Table 1). The intensities for the IL-6R mRNA
signal ranged from more heavily labeled cells containing up to 80
grains per cells to intensely labeled cells that exhibited the
strongest hybridization signal (Table 1, Fig. 1 C, E).
The labeling intensities of IL-6R mRNA were commensurate
with the parameters of bone resorption (Table 1). The most
intense hybridization signals for IL-6R mRNA in osteoclasts were
observed in the patients with the highest bone resorption, char-
acterized by dissective and tunneling resorption sites (Fig. 1E).
Also, within the same patient, osteoclasts found at the tip of
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Table 1. Serum parathyroid hormone (PTH) levels, parameters of bone resorption, IL-6 and IL-6R mRNA signal intensities in seven patients with
renal osteodystrophy
Patients
Serum
PTH
pg/mi Diagnosisa
Erosion/
bone surface
%
Osteoclast
number/bone
#1100 mm
Erosion
depth
jim
IL-6
mRNA"
IL-6R
mRNA"
1 380 MUO 4.8 73 24.2 +-t +
2 234 MUO 6.4 88 20.9 ++ +
3 262 MUO 7.3 106 21.5 ++ ++
4 421 MUO 10.6 164 17.9 ++ ++
5 874 PHPT 13.0 214 35.2 ++ --++
6 1007 PHPT 14.6 219 43.7 ++ ++++
7 1234 PHPT 25.9 281 33 ++ +++
a Abbreviations used: MUO, mixed uremic osteodystrophy; PHPT, predominant hyperparathyroid; IL-6, interleukin-6; IL-6R, interleukin-6 receptor.
"Criteria for grading mRNA signal levels were as follows: + <10 grains/cell; + + 10 to 50 grains/cell; + + + 50 to 80 grains/cell; + + + +, grains
confluent.
cutting cones of deep dissective Iacunae exhibited stronger hy-
bridization signal (Fig. 1E) than those in shallow surface resorp-
tion sites (Fig. 1C).
The bone marrow cells also contained positive hybridization
signals for IL-6 and IL-6R mRNAs (Fig. 2 A, B). The signal varied
but did not approach the intensity of IL-6R mRNA signal in
osteoclasts of deep dissective resorption lacunae. Osteoblasts and
osteocytes exhibited weak labeling which did not exceed the
background signal level. Control experiments confirmed the spec-
ificity of probes. Bone tissue sections serially processed that were
either probed with sense-strand riboprobes or pretreated with
RNAse A did not contain positive hybridization signals for IL-6 or
IL-6R mRNAs in specific bone tissue cells (Fig. 1 B, D).
Discussion
This report is in keeping with in vitro studies that demonstrated
the presence of IL-6 in multinucleated cells [3, 7, 8, 24—26]. It also
supports and further expands another in vivo report that mRNA
transcripts for IL-6 and IL-6R are expressed in bone cells of
patients with Paget's disease [11]. To our knowledge, the present
study provides the first molecular histologic evidence that mRNAs
for IL-6 and IL-6R are expressed in osteoclasts from undecalcified
human bone tissue of patients with renal failure. In contrast to the
findings from patients with Paget's disease, our study demon-
strates localization of IL-6 and IL-6R mRNAs in patients with
renal failure who should not have the potential problem of virally
infected osteoclasts. Thus, the present observation should repre-
sent a more physiologic example of in vivo osteoclastic expressions
of these mRNA transcripts. Together with data from patients with
Paget's disease, the present study raises the possibility that in
different bone diseases, local factors, including cytokines and their
receptors, exert their contribution to bone remodeling by regula-
tion of specific mRNA expression.
Our observation that osteoclasts have high levels of IL-6
mRNA expression confirms an earlier report noting that oste-
oclasts express significantly more IL-6 than osteoblasts [24]. The
present study did not detect significantly increased IL-6 and IL-6R
mRNA transcripts in osteoblasts, in contrast to the highly expres-
sive osteoclasts and bone marrow stromal cells. This observation
is in keeping with the in vitro data demonstrating that IL-6 does
not elicit cellular response from osteoblast-like cells [27]. How-
ever, it may be that low detectable IL-6 trancripts may be one of
the characteristics manifested in osteoblastic insufficiency de-
scribed in renal failure patients [2, 28]. Thus, it is possible that the
mRNA levels of IL-6 and IL-6R in osteoblasts may be too low to
be detected by our methodology in patients with renal failure
since osteoblasts of Pagetic bone appear to express these mRNA
species [11].
It is of interest that we observed positive labeling for IL-6 and
IL-6R mRNAs in bone marrow cells. It is clear that the bone
marrow gives rise to the progenitor cells for both osteoclasts and
osteoblasts [29]. In vitro studies indicate that these cells exhibit an
extensive overlap in their phenotypic characteristics including
expression of alkaline phosphatase and collagen type I [30, 31]
and secretion of IL-6 and other cytokines [32, 33]. Evidence from
animal models suggests that the bone marrow undergoes signifi-
cant cellular changes in response to cessation of ovarian function
and as a result of senescence [34, 351 These studies lend credence
to our observation in the bone microenvironment documenting
IL-6 mRNA expression in bone marrow cells. However, the IL-6
and IL-6R mRNA expression in marrow cells requires further
investigations that are beyond the scope of this report. Our
observation that IL-6 and IL-6R are expressed in bone marrow
cells suggests that this cytokine may play an autoregulatory
function.
IL-6 is a multifunctional cytokine that has been shown to have
profound effects on bone [1—4]. The bone loss associated with
ovariectomy in mice has been shown to be prevented by admin-
istration of an antibody to IL-6, linking it with the effects of
gonadal steroids such as estrogen on bone [36]. The novel finding
in our study of increased IL-6R mRNA expression in osteoclasts
suggests an interaction between these osteoclasts and bone re-
modeling, particularly in patients with high bone resorption.
Moreover, the cytokine IL-6 may be intimately involved in bone
resorption, potentially with osteoclast activation and, more impor-
tantly, expression of its receptor in osteoclasts appear to parallel
the levels of osteoclastic bone resorbing activity.
Although IL-6R mRNA expression in osteoclasts correlated
well with PTH levels, it is still not known whether PTH has a
direct effect on osteoclasts. Although recent in vitro and in vivo
data indicate that high PTH levels are associated with increased
production of IL-6 and IL-6R [27, 37, 38], PTH receptors have yet
to be detected in bone osteoclasts. Our present data support the
hypothesis that high PTH levels in patients with renal failure may
stimulate IL-6 and IL-oR mRNAs in osteoclasts but not osteo-
blasts. Thus, PTH could modulate osteoclastic activity through
other factors synthesized and secreted by osteoblasts and marrow
cells, including other cytokines and growth factors. It is well
t. *
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Fig. 1. Brightfleld photomicrographs of in Situ hybridization for IL-6 and IL-6R mRNAs in osteoclasts of bone sections (thickness 5 pin). Original
magnification x98; H and E counterstains. A. Osteoclasts in a resorption lacunae with positive hybridization signals for IL-6 mRNA. B. Serial section
of bone shown in A processed with sense-strand probe as control. No labeling was observed in osteoclasts. C. Positive hybridization signal for IL-6R
mRNA in osteoclasts of a surface resorption site. D. Serial section of bone shown in C processed through RNAse A pretreatment prior to hybridization
with antisense probe. No labeling was observed in osteoclasts. E. Osteoclasts at the tip of a dissective cutting cone from the same patient sampled in
C. Stronger hybridization signal was observed for IL-6R mRNA in osteoclasts (compared to C) of this more active resorptive site. F. Serial section of
bone shown in E with positive hybridization signal for IL-6 mRNA in osteoclasts. The IL-6 mRNA signal appear less intense than the IL-6R mRNA
signals in E. Publication of this figure in color was made possible by a grant from Dialysis Clinics Incorporated, Lexington, Kentucky, USA.
with secretion of osteoclast activity stimulatory factors. To our
knowledge, this report provides the first evidence that the immu-
nomodulatory cytokine, IL-6, and its receptor IL-6R, are associ-
ated with bone resorbing activity of osteoclasts. Continuing stud-
ies to identify cells that produce locally secreted cytokines and
their pattern of expression in patients with renal failure are
presently underway.
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